In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Word Pharma Today
BioMed X unveiled its new immunology discovery platform designed to allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs).
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Contract Pharma
The new technology functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
Yahoo!
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
GlobeNewswire
The underlying technology emerged from a collaboration between BioMed X and Janssen Research & Development, LLC (Janssen). An international team of outstanding early-career researchers was recruited through the unique BioMed X crowdsourcing model. During a five-year research project at the BioMed X Institute in Heidelberg, the team developed a new platform technology for “Rapid Identification of Auto-Antigens in Autoimmune Diseases.”
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
FinanzNachrichten
BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs). The research team led by John Lindner, who has developed the new technology, is based at the BioMed X Institute in Heidelberg, Germany.
Visit: BioMed X Launches New T Cell Immunology Discovery Platform
BioMed X Launches New T Cell Immunology Discovery Platform
BioSpace
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for immunology discovery.
Visit: Novel Alliance Responds to Big Pharma’s Most Pressing AI/ML Needs
Novel Alliance Responds to Big Pharma’s Most Pressing AI/ML Needs
BioSpace
Artificial intelligence and machine learning applications are not the future of drug development; they’re already here, being deployed at large pharmaceutical companies like Pfizer and Merck KGaA.